Application No.: 10/517,909

Office Action Dated: August 29, 2007

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1 to 12 (cancelled)

13. *(previously presented)* A compound of formula I:

wherein:

 R_1 is aromatic group, where said aryl is optionally substituted by one or more atoms or groups of atoms selected from the group consisting of halogen, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, nitro, cyano, trifluoromethyl, and trifluoromethoxy;

Ι

 R_2 is hydrogen or C_1 - C_4 alkyl, where said C_1 - C_4 alkyl is optionally monosubstituted by a phenyl or -CONH₂ or optionally substituted by one or more fluorine atoms;

R₃ is hydrogen or hydroxy;

R₄ is hydrogen;

or R_4 , together with R_3 , forms a -CH=N- or a straight or branched C_2 - C_4 alkylene;

R₅ is hydrogen or C₁-C₃ alkyl;

R₆ is hydrogen or halogen;

Y is straight or branched saturated C_2 - C_4 alkylene or straight or branched unsaturated C_2 - C_4 alkylene, where said C_2 - C_4 alkylene is optionally interrupted between two carbon atoms by an oxygen atom;

or an acid addition salt thereof.

Application No.: 10/517,909

Office Action Dated: August 29, 2007

14. (previously presented) A compound according to claim 13,

wherein R_1 is chlorophenyl, dichlorophenyl, trichlorophenyl, chloromethoxyphenyl, chloro-trifluoromethoxyphenyl, dichloro-trifluoromethyl-phenyl, chlorofluorophenyl, difluorophenyl, trifluoromethyl-phenyl, trifluoromethyl-methoxyphenyl, trifluoromethyl-chlorophenyl trifluoromethoxy-phenyl, tolyl, chlorotolyl, dichlorotolyl, dimethyltolyl, methoxytolyl, methoxy-methyltolyl, dichloromethoxy, trifluoromethoxy-tolyl, naphthyl, nitrophenyl, trifluoromethyl-nitrophenyl, cyanophenyl, or thienyl.

15. (previously presented) A compound according to claim 13,

wherein R_1 is phenyl substituted by one or more atoms or groups of atoms selected from the group consisting of halogen, C_1 - C_3 alkyl, and C_1 - C_3 alkoxy.

- 16. (previously presented) A compound according to claim 13, wherein R_2 is C_1 - C_4 alkyl.
- 17. (previously presented) A compound according to claim 13, wherein R₂ is hydrogen, methyl, cyclopropyl, trifluoroethyl, isopropyl, -CH₂CONH, -(CH₂)₂CONH, or phenethyl.
- 18. *(previously presented)* A compound according to claim 13, wherein R₃ is hydrogen.
- 19. *(previously presented)* A compound according to claim 13, wherein R₃ is hydroxy.
- 20. *(previously presented)* A compound according to claim 13, wherein R₄ is hydrogen.
- 21. (previously presented) A compound according to claim 13, wherein R_3 and R_4 together form a -N=CH- or C_2 - C_3 alkylene. Page 3 of 20

PATENT

DOCKET NO.: CBDL-0056 **Application No.:** 10/517,909

Office Action Dated: August 29, 2007

- 22. (previously presented) A compound according to claim 13, wherein R₃ and R₄ together form -N=CH-, -(CH₂)₂-, or -CH₂-C(CH₃)₂-.
- 23. *(previously presented)* A compound according to claim 13, wherein R₅ is hydrogen, methyl, ethyl, or isopropyl.
- 24. (previously presented) A compound according to claim 13, wherein R_6 is hydrogen, difluoro, or dichloro.
- 25. *(previously presented)* A compound according to claim 13, wherein R₅ and R₆ are hydrogen.
- 26. *(previously presented)* A compound according to claim 13, wherein Y is saturated C₂-C₄ alkylene or saturated C₂-C₄ alkylene interrupted by an oxygen atom.
- 27. (previously presented) A compound according to claim 13, wherein Y is -(CH₂)₂-, -(CH₂)₃-, -(CH₂)₄-, -CH₂-CH=CH-, -(CH₂)₂-O-CH₂-, or

- 28. (previously presented) A compound according to claim 13, wherein Y is $-(CH_2)_4$ -.
- 29. *(previously presented)* A compound according to claim 13, wherein Y is $-(CH_2)_2$ -O- CH_2 -.
- 30. (currently amended) A compound according to claim 13,

Office Action Dated: August 29, 2007

wherein said compound is:

5-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;

4-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-butanamide;

3-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-propanamide;

4-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-(2E)-2-butenamide;

5-[[(2-chlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;

(2E)-4-[[(2-chlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

3-[[(2,3-dichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-propanamide;

4-[[(2,3-dichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-butanamide;

5-[[(2,3-dichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;

(2E)-4-[[(2,3-dichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

5-[[(2,6-dichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;

(2E)-4-[[(2,6-dichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

5-[methyl[(1-naphthalenyl)sulphonyl]amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;

(2E)-4-[methyl[(1-naphthalenyl)sulphonyl]amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

Office Action Dated: August 29, 2007

- 5-[[(2-chlorophenyl)sulphonyl]cyclopropylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;
- 5-[cyclopropyl[(2,3-dichlorophenyl)sulphonyl]amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;
- 5-[cyclopropyl[(2,6-dichlorophenyl)sulphonyl]amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;
- 5-[[(2,6-dichlorophenyl)sulphonyl](1-methylethyl)amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;
- 5-[(2-amino-2-oxoethyl)[(2,4-dichloro-3-methylphenyl)sulphonyl]-amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;
- 5-[(3-amino-3-oxopropyl)[(2,4-dichloro-3-methylphenyl)sulphonyl]-amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;
- 3-[[(2,3-dichlorophenyl)sulphonyl](1-methylethyl)amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-propanamide;
- 3-[[(2,6-dichlorophenyl)sulphonyl](1-methylethyl)amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-propanamide;
- 2-[2-[[(2-chlorophenyl)sulphonyl]cyclopropylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;
- 2-[2-[cyclopropyl[(2,3-dichlorophenyl)sulphonyl]amino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;
- 2-[2-[cyclopropyl[(2,6-dichlorophenyl)sulphonyl]amino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;
- 2-[2-[[(2,4-dichloro-3-methylphenyl)sulphonyl](2-phenylethyl)-amino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methylacetamide;
- 3-[[(2,6-dichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-propanamide;
- 3-[cyclopropyl[(2,3-dichlorophenyl)sulphonyl]amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-propanamide;

Office Action Dated: August 29, 2007

3-[cyclopropyl[(2,6-dichlorophenyl)sulphonyl]amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-propanamide;

3-[(2,2,2-trifluoroethyl)[(2,3-dichlorophenyl)sulphonyl]amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-propanamide;

3-[(2,2,2-trifluoroethyl)[(2,6-dichlorophenyl)sulphonyl]amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-propanamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2yl)phenyl]methyl]-N-methyl-4-[methyl[[2-(trifluoromethyl)phenyl]sulphonyl]amino]-(2E)-2-butenamide;

4-[[(2,4-dichloro-3-methylphenyl)sulphonyl]amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-(2E)-2-butenamide;

5-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]-N-[[4-(5,5-dimethyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;

5-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]-N-[[4-(5,5-

dimethyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide; 2-[2-[[(2,3-dichlorophenyl)sulphonyl]methylamino]ethoxy]-N-methyl-N-[[4-

(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]methyl]acetamide;

2-[2-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2,3-dichlorophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2,3-dichlorophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2,6-dichlorophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2-chlorophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

Office Action Dated: August 29, 2007

2-[2-[[(2,3-dichlorophenyl)sulphonyl]methylamino]ethoxy]-N-[[2-fluoro-4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2,3-dichlorophenyl)sulphonyl]methylamino]propoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2,3-dichlorophenyl)sulphonyl]methylamino]ethoxy]-N-methyl-N-[[4-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]methyl]acetamide;

2-[2-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2,3-dichlorophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-[2-[methyl[[2-(trifluoromethyl)phenyl]sulphonyl]amino]ethoxy]-acetamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulphonyl]methylamino|ethoxy|-N-methyl-acetamide;

2-[2-[[(2,4-dichlorophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2,4-dichloro-5-methylphenyl)sulphonyl]methylamino]-ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-[2-[methyl[(2-nitrophenyl)sulphonyl]amino]ethoxy]acetamide;

2-[2-[[[2,6-dichloro-4-(trifluoromethyl)phenyl]sulphonyl]-methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2-chloro-3-methylphenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2-cyanophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-[2-[methyl[(2,3,4-trichlorophenyl)sulphonyl]amino]ethoxy]acetamide;

Office Action Dated: August 29, 2007

2-[2-[[(3-chloro-2-methylphenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2-chloro-4-cyanophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-[2-

[methyl[[2-nitro-4-(trifluoromethyl)phenyl]sulphonyl]amino]-ethoxy]acetamide;

2-[2-[[(2,6-difluorophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-[2-[methyl[[4-(trifluoromethoxy)phenyl]sulphonyl]amino]-ethoxy]acetamide;

2-[2-[[(2,5-dichlorothien-3-yl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-[2-[methyl[(3-methylphenyl)sulphonyl]amino]ethoxy]acetamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-[2-[methyl(1-naphthalenylsulphonyl)amino]ethoxy]acetamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-[2-[methyl[[3-(trifluoromethyl)phenyl]sulphonyl]amino]-ethoxy]acetamide;

2-[2-[[(4-chloro-3-methylphenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2,4-difluorophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(3-chlorophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-5-[methyl[[2-(trifluoromethyl)phenyl]sulphonyl]amino]pentanamide;

5-[[(2,4-dichloro-5-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl-N-methyl-5-[methyl[(3-methylphenyl)sulphonyl]amino]pentanamide;

Office Action Dated: August 29, 2007

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-5-[[(4-methoxy-2,6-dimethylphenyl)sulphonyl]methylamino]-N-methyl-pentanamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl-N-methyl-5-[methyl[(2,3,4-trichlorophenyl)sulphonyl]amino]pentanamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl-N-methyl-5-[methyl[(2-nitrophenyl)sulphonyl]amino]pentanamide;

5-[[(2,4-dichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;

5-[[(2-chloro-3-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;

N-[[4-[amino(hydroxyimino)methyl]phenyl]methyl]-5-[[(2,4-dichloro-3-methyl)phenyl]sulphonyl]methylamino]-N-methyl-pentanamide

N-[[4-(aminoiminomethyl)phenyl]methyl]-5-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]-N-methyl-pentanamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulphonyl]methylamino]ethoxy]-N-methyl-acetamide;

N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-4-[methyl[[2-(trifluoromethyl)phenyl]sulphonyl]amino]-(2E)-2-butenamide;

N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-4-[methyl[[2-(trifluoromethyl)phenyl]sulphonyl]amino]-(2E)-2-butenamide;

4-[[(2,3-dichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)-2-fluorophenyl]methyl]-N-methyl-(2E)-2-butenamide;

4-[[(2-chlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)-2-fluorophenyl]methyl]-N-methyl-(2E)-2-butenamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-3-[[(4-methoxy-2,6-dimethylphenyl)sulphonyl]methylamino]-N-methyl-propanamide;

N-[[2-chloro-4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-5-[[(4-methoxy-2,6-dimethylphenyl)sulphonyl]methylamino]-N-methyl-pentanamide;

N-[[2-chloro-4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-5-[[(4-methoxy-2,6-dimethylphenyl)sulphonyl]methylamino]-N-methyl-pentanamide;

Office Action Dated: August 29, 2007

N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-[2-[methyl][2-(trifluoromethyl)phenyl]sulphonyl]amino]-ethoxy]acetamide;

N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-[2-[methyl][2-(trifluoromethyl)phenyl]sulphonyl]amino]-ethoxy]acetamide;

N-[[2-chloro-4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-2-[2-[[(2-chlorophenyl)sulphonyl]methylamino]ethoxy]-N-methyl-acetamide;

N-[[2-chloro-4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulphonyl]methylamino]ethoxy]-N-methyl-acetamide;

N-[[4-(4,5-dihydro-1-(1-methylethyl)-1*H*-imidazol-2-yl)phenyl]-methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulphonyl]methyl-amino]ethoxy]-N-methyl-acetamide;

N [[4 (4,5 dihydro 1 (1 methylethyl) 1*H* imidazol 2 yl)phenyl] methyl] 2 [2 [[(4 methoxy 2,6 dimethylphenyl)sulphonyl] methylamino]ethoxy] N methylacetamide;

N-[[2-chloro-4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]-methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulphonyl]methyl-amino]ethoxy]-N-methyl-acetamide;

N-[[2-chloro-4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]-methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulphonyl]methyl-amino]ethoxy]-N-methyl-acetamide;

N-[[2-chloro-4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]-methyl]-N-methyl-2-[2-[methyl[[2-(trifluoromethyl)phenyl]-sulphonyl]amino]ethoxy]acetamide;

N-[[2-chloro-4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]-methyl]-N-methyl-2-[2-[methyl[[2-(trifluoromethyl)phenyl]-sulphonyl]amino]ethoxy]acetamide;

2-[2-[[(2-cyanophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2-cyanophenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

2-[2-[[(2-chloro-4-methoxyphenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

Office Action Dated: August 29, 2007

2-[2-[[(2-chloro-4-methoxyphenyl)sulphonyl]methylamino]ethoxy]-N-[[4-(4,5-dihydro-1-methyl-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide;

N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl-N-methyl-3-[methyl[[2-(trifluoromethyl)phenyl]sulphonyl]amino]propanamide;

N-[[4-(1-ethyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-[2-[methyl[[2-(trifluoromethyl)phenyl]sulphonyl]-amino]ethoxy]acetamide;

N-[[4-[1-(1-methylethyl)-4,5-dihydro-1*H*-imidazol-2-yl]phenyl]-methyl]-N-methyl-2-[2-[methyl[[2-(trifluoromethyl)phenyl]-sulphonyl]amino]ethoxy]acetamide;

N-[[4-(1*H*-1,2,4-triazol-5-yl)phenyl]methyl]-N-methyl-2-[2-[methyl-[(4-methoxy-2,6-dimethylphenyl)sulphonyl]amino]ethoxy]acetamide;

(2E)-4-[[(2-chloro-4-fluorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

(2E)-4-[[[2,6-dichloro-4-(trifluoromethyl)phenyl]sulphonyl]methyl-amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

(2E)-4-[[(2,6-difluorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

(2E)-4-[[(2-nitrophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

(2E)-4-[[(2,4,6-trimethylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

(2E)-4-[[(2,5-dichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

(2E)-4-[[(2,4-dichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

(2E)-4-[[(3-chloro-2-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

(2E)-4-[[(2-cyanophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

Office Action Dated: August 29, 2007

(2E)-4-[[(2-chloro-4-methoxyphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;

- (2E)-4-[[(2,4-dichloro-5-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;
- (2E)-4-[[(2,3,4-trichlorophenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;
- (2E)-4-[[[2-chloro-4-(trifluoromethoxy)phenyl]sulphonyl]-methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;
- (2E)-4-[[[4-methoxy-2-(trifluoromethyl)phenyl]sulphonyl]methyl-amino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;
- (2E)-4-[[(4-methoxy-2,6-dimethylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-2-butenamide;
- 5-[[(2-chloro-4-methoxyphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;
- 5-[[(4-methoxy-2-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;
- 5-[[[2-methyl-4-(trifluoromethoxy)phenyl]sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;
- 5-[[[4-methoxy-2-(trifluoromethyl)phenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide;
- 2-[2-[[(2-chloro-4-methoxyphenyl)sulphonyl]methylamino]ethoxy]-N-[[4-
- (4,5-dihydro-1 H-imidazol-2-yl) phenyl] methyl]-N-methyl-acetamide;
 - 2-[2-[[(4-methoxy-2-methylphenyl)sulphonyl]methylamino]ethoxy]-N-[[4-
- (4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl]-N-methyl-acetamide; or an acid addition salt thereof.
- 31. *(previously presented)* A compound according to claim 30, wherein said acid addition salt is hydrochloride, fumarate, or trifluoroacetate.

Application No.: 10/517,909

Office Action Dated: August 29, 2007

32. *(previously presented)* A method for preparing a compound according to claim 1 or an acid addition salt thereof, comprising the steps consisting of:

a) reacting an acid of formula II:

$$R_1$$
 N COOH R_2 II

wherein

 R_1 is aryl, where said aryl is optionally substituted by one or more atoms or groups of atoms selected from the group consisting of halogen, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, nitro, cyano, trifluoromethyl, and trifluoromethoxy;

 R_2 is hydrogen or C_1 - C_4 alkyl, where said C_1 - C_4 alkyl is optionally monosubstituted by a phenyl or -CONH₂ or optionally substituted by one or more fluorine atoms;

Y is straight or branched saturated C_2 - C_4 alkylene or straight or branched unsaturated C_2 - C_4 alkylene, where said C_2 - C_4 alkylene is optionally interrupted between two carbon atoms by an oxygen atom; R_1 is an aromatic system that is non-substituted or substituted by one or more atoms or groups of atoms selected from the group consisting of halogen, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, nitro, cyano, trifluoromethyl and trifluoromethoxy;

with an amine of formula III:

$$H-N-CH_{2} \xrightarrow{R_{6}} N-R_{3} \xrightarrow{R_{4}} R_{4}$$

Ш

wherein

R₃ is hydrogen;

R₄ is hydrogen;

Office Action Dated: August 29, 2007

or R_4 , together with R_3 , forms a -CH=N- or a straight or branched C_2 - C_4 alkylene;

R'₅ is hydrogen, C₁-C₃ alkyl, or an amino-protecting group;

R₆ is hydrogen or halogen;

wherein the reaction being conducted in a solvent in the presence of at least one activator agent at a temperature of room temperature to 60°C to obtain the amide of formula:

wherein

 R_1 is aryl, where said aryl is optionally substituted by one or more atoms or groups of atoms selected from the group consisting of halogen, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, nitro, cyano, trifluoromethyl, and trifluoromethoxy;

 R_2 is hydrogen or C_1 - C_4 alkyl, where said C_1 - C_4 alkyl is optionally monosubstituted by a phenyl or -CONH₂ or optionally substituted by one or more fluorine atoms;

R₃ is hydrogen;

R₄ is hydrogen;

or R_4 , together with R_3 , forms a -CH=N- or a straight or branched C_2 - C_4 alkylene;

R'₅ is hydrogen, C₁-C₃ alkyl, or an amino-protecting group;

R₆ is hydrogen or halogen; and

Y is straight or branched saturated C_2 - C_4 alkylene or straight or branched unsaturated C_2 - C_4 alkylene, where said C_2 - C_4 alkylene is optionally interrupted between two carbon atoms by an oxygen atom; R_1 is an aromatic system that is non-substituted or substituted by one or more atoms or groups

Application No.: 10/517,909

Office Action Dated: August 29, 2007

of atoms selected from the group consisting of halogen, C₁-C₃ alkyl, C₁-C₃ alkoxy, nitro, cyano, trifluoromethyl and trifluoromethoxy;

b) if necessary, when said R'₅ is an amino-protecting group, reacting said compound of formula IV to remove said amino-protecting group and replace it by hydrogen, thereby obtaining said compound of formula I, where R₅ is hydrogen;

c) if necessary, reacting said compound of formula IV or compound of formula I with a mineral or organic acid to obtain said acid addition salt of said compound of formula IV or said compound of formula I.

33. *(previously presented)* A composition, comprising:

at least one compound according to claim 13 or an acid addition salt thereof; and

at least one physiologically suitable excipient.

34. *(previously presented)*A method for treating pain or an inflammatory disease, comprising the step of:

administering to a mammal in need thereof an effective amount of a compound according to claim 13 or an acid addition salt thereof.